Some regard race-based medical treatment as necessary to reduce health disparities, while others view it as downright discriminatory. When BiDil was approved, Francis Collins, who was Director of the US National Human Genome Research Institute at the time, warned that “we should move without delay from blurry and potentially misleading surrogates for drug response, such as race, to the more specific causes.”
有人提出为了缩小健康差异医学治疗有必要区分种族，但也有人认为这是彻头彻尾的歧视。BiDil获批时，时任美国国家人类基因组研究所主任弗朗西斯·柯林斯警告说“我们应当毫不犹豫地放弃研究种族等模糊并可能构成误导的药物反应替代因素，转而对更具体的原因进行研究。”